USAEUROPEViVE
ABOUTSPONSORSHIPFOUNDATION
Logo Hlth
Logo Hlth
16 Feb 2023 | 03:45 PM GMT

Digital Biomarkers for Mental Health Evaluation and Management

Anchored by:

George Eleftheriou
CEO & Co-Founder
FEEL THERAPEUTICS

Participants:

George Eleftheriou CEO & Co-FounderFeel Therapeutics
George Eleftheriou
CEO & Co-FounderFeel Therapeutics
Myles Furnace Chief Commercial OfficerEolas Medical
Myles Furnace
Chief Commercial OfficerEolas Medical
Anand Trivedi ZSConsultant
Anand Trivedi
ZSConsultant
Benjamin Alouf Chief Medical OfficerFloreo
Benjamin Alouf
Chief Medical OfficerFloreo
Dr. Nick (Nemanja) Kovacev Head of Healthcare and Life Sciences PracticeHTEC Group
Dr. Nick (Nemanja) Kovacev
Head of Healthcare and Life Sciences PracticeHTEC Group
Julia Scott XRSI Medical Council LeadXRSI - XR Safety Intelligence
Julia Scott
XRSI Medical Council LeadXRSI - XR Safety Intelligence
Marta Sole Venture Innovation ManagerMon Clinic
Marta Sole
Venture Innovation ManagerMon Clinic
Masayuki ‘Masa’ Asano Head of Partnership and Business DevelopmentMelon Inc.
Masayuki ‘Masa’ Asano
Head of Partnership and Business DevelopmentMelon Inc.
Polina Veltmann Co-founder & CEOOrly Health
Polina Veltmann
Co-founder & CEOOrly Health
PV
Polina Veltmann CEOevoleen
PV
Polina Veltmann
CEOevoleen
Stuart Adams Chief Strategy Officer (CSO)CLINICOM
Stuart Adams
Chief Strategy Officer (CSO)CLINICOM

About this Meeting

Small, intimate and participant-led discussions tackling digital health challenges. Spaces are limited to 8 - 12 people, allowing you to focus on quality in-depth conversations.

Unlike other therapeutic areas, mental health evaluation and management can be a bit of an art, and at times relies on subjectivity in the outcomes analysis. However, digital tools could help improve this through the collection of consumer-generated physiological and behavioural measures. Mental health patients can be evaluated using digital biomarkers obtained from smartphones and sensors, such as phone usage, activity, text and voice characteristics.

How to use the data from everyday technologies and other specialised sensors to remotely and continuously measure individuals’ mental health? Join this session to discuss with your peers: 

  • Clinical validation of digital biomarkers for mental health evaluation and management. What digital biomarkers have been clinically validated so far? How can we validate new ones, what are the standards, guidelines and regulatory considerations to follow? 
  • What is real now and limitations of the current digital biomarkers in mental health. What are some real examples of digital biomarkers improving diagnosis, treatment and monitoring? What are the current limitations and challenges (e.g. bias, interpretability, data privacy, reliability, etc.)? 
  • The use of digital biomarkers in therapy and treatment. How to use these biomarkers to personalise therapy? How can digital biomarkers be used to monitor the progress of therapy and treatment and adjust as needed? 
  • Other challenges when using digital biomarkers in psychiatry and how to overcome them: data collection, data integration, interpretation, privacy, regulations, health equity, etc.)? 
  • The future for digital biomarkers in mental health. How will these technologies change the diagnosis and management guidelines in mental health? What needs to happen so we start seeing these biomarkers as day to day tools for mental health professionals?
We would like to remind you that our meetings are small and intimate sessions with a limited number of seats available, therefore we rely on your attendance and participation to ensure a high quality and valuable meeting for all. If you are confirmed for this meeting we ask if you can please ensure your attendance on the day.